BioCentury | Jul 2, 2020
Product Development

July 1 Quick Takes: Amgen gains on court win; plus Hua, J&J, argenx, Seattle Genetics-Genmab, Interprotein

...Appeals court upholds Enbrel patents Amgen Inc. (NASDAQ:AMGN) shares rose 8% Wednesday, adding more than $11...
...a 2019 district court decision affirming the validity of two patents covering autoimmune drug Enbrel etanercept...
BioCentury | May 1, 2020
Regulation

China's proposed annual NRDL revisions could increase pricing pressure

...such as stroke therapy butylphthalide from CSPC Pharmaceutical Group Ltd. (HKSE:1093) and autoimmune drug and etanercept...
BioCentury | Apr 11, 2020
Emerging Company Profile

Clover: trimerizing fusion proteins

...longer add new candidates to its pipeline. The most advanced is its biosimilar of Enbrel etanercept...
...superfamily member 10b TRAIL - Tumor necrosis factor-related apoptosis-inducing ligand Hongjiang Li, Staff Writer SCB-313 biosimilar etanercept (SCB-808) SCB-313 biosimilar etanercept...
BioCentury | Jan 10, 2020
Product Development

Seeking structural endpoints for OA

...Amgen Inc. (NASDAQ:AMGN) in the 1990s as part of the team that developed TNF inhibitor Enbrel...
BioCentury | Nov 6, 2019
Company News

Biogen expanding biosimilars deal for eye therapies, anti-TNFs

...China to three biosimilars the company already markets in Europe: Benepali etanercept, a biosimilar of Enbrel...
...NYSE:MRK) holds territorial rights to biosimilars including Ontruzant trastuzumab, Hadlima adalimumab, Reflexis infliximab and Brenzys etanercept...
BioCentury | Oct 9, 2019
Politics, Policy & Law

Long-term data help two drugs sway ICER in drug price report

...of their drugs were lower than SSR’s estimate: Avonex interferon beta-1 from Biogen and Enbrel etanercept...
BioCentury | Aug 26, 2019
Company News

With Celgene's $13.4B sale of Otezla, Amgen adds to anti-inflammatory franchise

...particularly in Europe and Japan. Otezla will complement Amgen's existing anti-inflammatory franchise led by Enbrel etanercept...
...most recent annual report, the last two U.S. patents giving the company market exclusivity for Enbrel...
...launch the biosimilar Erelzi etanercept-szzs in the U.S.; it already markets the biosimilar in Europe. Etanercept...
BioCentury | Aug 16, 2019
Company News

Rinvoq approval bolsters AbbVie's autoimmune portfolio

...The WAC of autoimmune drug Xeljanz tofacitinib from Pfizer Inc. (NYSE:PFE) is $53,768, while Enbrel etanercept...
BioCentury | Aug 9, 2019
Company News

Enbrel ruling lifts Amgen shares

...New Jersey late Friday removed a key overhang on Amgen shares when it upheld two Enbrel...
...a BLA to FDA for its Enbrel biosimilar Erelzi etanercept-szzs (see "Amgen Suing Sandoz Over Enbrel...
...2016 became the first etanercept biosimilar to be approved by FDA (see "FDA Approves Sandoz's Enbrel...
BioCentury | Aug 8, 2019
Translation in Brief

Lab mice with ‘wild’ microbiomes better reflect clinical data

...product expanded anti-inflammatory Treg cell numbers. In another instance, tumor necrosis factor α inhibitor Enbrel etanercept...
...As in the clinical trials, a tool compound version of TGN1412 induced cytokine storm, and Enbrel...
Items per page:
1 - 10 of 1001